TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06742853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic Acid
Description: Bempedoic Acid tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bempedoic Acid
Description: Bempedoic Acid tablet will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06749392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive-expressive treatment
Description: Sixteen weeks of a time-limited psychodynamic therapy adapted for depression that includes the use of expressive techniques, such as interpretation, confrontation, clarification and the use of supportive techniques, such as affirmation and empathic validation. This treatment postulates insight as its core mechanism of change.
Study: NCT06756646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: The aerobic exercise intervention will utilize an ergometer. The program will be conducted 2-3 times per week over a 3-month period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease and exercise suggestion
Description: The participants will be provided by educational program about COPD self-care and home-based exercise approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) intervention
Description: Blood flow restriction (BFR) intervention will combine aerobic exercise on the ergometer with BFR training. The program will be conducted 2-3 times per week over a 3-month period.
Study: NCT06757335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP568
Description: In the I/II stage: HP568 administered QD or BID for 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP568 in combination with palbociclib
Description: In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
Study: NCT06758336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) for 10 minutes. After rested for 15 minutes, the participants underwent tests.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
Study: NCT06758284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: The first component of the intervention is laughter therapy, which is a combination of warm-up exercises, deep breathing exercises, childlike playfulness and laughter exercises. Participants will do laughter therapy via WhatsApp video call. Laughter yoga will be a single session and will last approximately 30 minutes.
Study: NCT06756698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment plus music intervention
Description: Each music therapy session will include 5 stages. In stage 1, an emotional assessment is conducted to observe the patient's current emotional experience and feelings (provide a VAD score), which lasts about 1 minute. In stage 2, relaxation exercises (breathing relaxation, progressive muscle relaxation, and imaginary relaxation) are conducted under the guidance of the therapist to the music corresponding to the relaxation target VAD, which lasts about 8 minutes. In stage 3, the patient independently selects the music and discusses it with the therapist, which lasts about 10 minutes. In stage 4, the patient listens to resource and positive-oriented music and discusses specific topics with the therapist, which lasts about 10 minutes. Finally, in stage 5, the therapist again conducts an emotional assessment of the patient and observes the patient's current emotional experience and feelings, which lasts about 1 minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: The conventional treatment group received DBT group therapy 5 times a week, each session lasting 1 hour, and also received individual personalized therapy twice a week.
Study: NCT06757309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Intervention consists in personalized counseling to adopt the Mediterranean diet, focusing on whole foods, healthy fats, and lean proteins. Participants receive tailored meal plans, educational materials, and practical tips. Follow-up sessions at weeks 4 and 12 offer support, progress reviews, and goal-setting to ensure adherence and improved health outcomes
Study: NCT06758219

Intervention type: OTHER
Intervention: There is no intervention in the study.
Description: There is no intervention in the study.
Study: NCT06758492

Intervention type: DEVICE
Intervention: Video laryngoscopy used to insert thin endotracheal catheter
Description: Video laryngoscopy used to insert thin endotracheal catheter

Intervention type: DEVICE
Intervention: Direct laryngoscopy used to insert thin endotracheal catheter
Description: Direct laryngoscopy used to insert thin endotracheal catheter
Study: NCT06758401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sigvotatug Vedotin
Description: MMAE-Antibody Drug Conjugate targeting Integrin Beta-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Anti-PD-(L)1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Anti-PD-(L)1
Study: NCT06757868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amobarbital
Description: Amobarbital 1mg/kg is given prior to cardiopulmonary bypass

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam 0.1mg/kg is given prior to cardiopulmonary bypass
Study: NCT06758310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Exercise
Description: Each participant will be prescribed an individualized exercise program related to their fitness testing results and personal interests.
Study: NCT05839210

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Supportive Materials
Description: Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Materials
Description: Participants will receive an informational study notebook, an exercise reference poster and videos, a Fitbit, and three stretch bands of different intensities. Participants will also receive supportive and informational text messages or emails three (3) times per week during the study; participants can opt-out of these messages.~Participants will be requested to utilize the Fitbit app to track exercise sessions, as well as the MyFitnessPal app to track their diet. Support to set up apps will be provided by research staff. For participants who choose not to use the app, a laminated diet and exercise tracking sheet with dry erase marker will be provided, and participants will be advised to send a picture of their completed tracking sheet by text message to research staff each week.
Study: NCT06758453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Challenge
Description: Ingestion of a high-fat, high-glucose meal to induce postprandial variations in bile acids and other metabolic markers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Challenge
Description: Ingestion of a high-fat, high-glucose meal to induce postprandial variations in bile acids and other metabolic markers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Challenge
Description: Ingestion of a high-fat, high-glucose meal to induce postprandial variations in bile acids and other metabolic markers.
Study: NCT06756451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJK-RT2831 dose-escalation phase Ia
Description: there are seven doses(1mg-160mg) in this part. The subjects will receive RJK-RT2831 injection twice a week by intravenous push or intravenous infusion for 4 weeks until the end of one dosing cycle (28 days). After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJK-RT2831 Dose Expansion Phase Ib
Description: there are four doses in this part. The subjects will be randomized in a 1:1 ratio to receive one dose level of RJK-RT2831 intravenous infusion twice a week for 4 weeks until the end of one dosing cycle (28 days).After one dosing cycle, if the subject tolerates, the subject will continue to receive treatment until the researcher believes that the subject no longer benefits, or the subject has disease progression, unacceptable toxicity, withdraws informed consent, dies, is lost to follow-up, or starts new anti-tumor treatment (whichever occurs first).
Study: NCT06199193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Personalized diet
Description: Personalized supplement designed by artificial intelligence based on the intestinal microbiota and incorporated into diets

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Dietary counseling
Description: Dietary advice will be provided to adapt the diet to the nutritional objectives and recommended intakes.
Study: NCT05810233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1000mg
Description: Health supplement
Study: NCT05277246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigant concentration
Description: The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigant concentration
Description: The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Irrigant concentration
Description: The success of endodontic treatment is directly related to infection control. In successful endodontic treatment, it is necessary to perform an ideal irrigation both in order to gain a better understanding of the complex anatomical structure of the root canals and to increase the efficiency of the instruments and methods used during the canal preparation. Sodium hypochlorite (NaOCl) solution is the standard irrigation agent for cleaning and disinfection of root canal. In this study, the effect of NaOCI on level of IL-8 different concentration will be evaluated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaOCI
Description: NaOCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaOCI
Description: NaOCI
Study: NCT05177835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: All subjects will receive ABX464 given at 25 mg QD.
Study: NCT05277246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaOCI
Description: NaOCI
Study: NCT05810233

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose chewable tablet without any ascorbic acid
Study: NCT04740671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04-O
Description: Biologic recombinant anti-VEGF humanized monoclonal antibody, developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Biologic anti-VEGF recombinant humanized monoclonal antibody fragment
Study: NCT06339801

Intervention type: DEVICE
Intervention: MiVu
Description: All patients will undergo mucosal impedance (MI) measurement using the MiVu™ Mucosal Integrity Testing System (Diversatek Healthcare, Inc.).
Study: NCT05786456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in group and web-based self-study sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive handouts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Participate in check-in calls
Study: NCT06436274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GARDASIL®9
Description: GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®9
Description: GARDASIL®9 or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo®/Menactra®
Description: Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo®/Menactra®
Description: Menveo®/Menactra® or equivalent vaccines will be used for this study. These are FDA-approved vaccines.
Study: NCT06412471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-707
Description: bispecific antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/L1
Description: Immune checkpoint inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/L1
Description: Immune checkpoint inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: chemotherapy
Study: NCT06581744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]AlF-NOTA-Pentixather
Description: inject 185\~370MBq \[18F\]AlF-NOTA-Pentixather
Study: NCT05709379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Description: Interrupting sitting with walking/jogging at either high -or low physical activity intensity.
Study: NCT05191875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saccharomyces Boulardii 250 MG
Description: Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory

Intervention type: DRUG
Group type: OTHER
Intervention: Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate
Description: Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD
Study: NCT05773885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)
Description: The patients will carry out motor, speech, and cognitive rehabilitation exercises using the VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy).~The motor exercises will be performed using inertial sensors for the acquisition and processing of the movement performed by the patient. This data is shown to the patient with visual and auditory feedback in a serious games environment. The exercises will cover the rehabilitation of balance and lower limbs, for example Balance on one leg, March in place, Stand on tiptoe, Squat, etc. The physiotherapists involved in the study will define a protocol of exercises in TR mode customized according to the characteristics and needs of the patient. The exercises in the speech therapy and cognitive domains will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: The patients will carry out conventional rehabilitation treatments (including physiotherapy, occupational therapy, speech therapy, psychotherapy) without the use of any technological devices.~The motor exercises will concern the rehabilitation of balance, trunk, and lower limbs and will be performed with a physiotherapist who will customize the treatment based on the characteristics and needs of the patient. The occupational therapy, speech therapy, psychotherapy treatments will be defined by the specialized staff based on the characteristics of the patient.~The duration of the rehabilitation treatments is 9 hours per week.
Study: NCT06280521

Intervention type: OTHER
Group type: OTHER
Intervention: fGQ-ASC
Description: French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)

Intervention type: OTHER
Group type: OTHER
Intervention: fGQ-ASC
Description: French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)

Intervention type: OTHER
Group type: OTHER
Intervention: fGQ-ASC
Description: French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)

Intervention type: OTHER
Group type: OTHER
Intervention: fGQ-ASC
Description: French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC)